Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DDKF39
|
|||
| Drug Name |
Evenamide
|
|||
| Synonyms |
1092977-61-1; 2-((3-Butoxyphenethyl)amino)-N,N-dimethylacetamide; UNII-ON5S6N53JS; ON5S6N53JS; MFCD28502433; 2-[(3-Butoxyphenethyl)amino]-N,N-dimethylacetamide; Evenamide [INN]; SCHEMBL3025285; CHEMBL3678076; 2-((2-(3-Butoxyphenyl)ethyl)amino)-N,N-dimethylacetamide; Acetamide, 2-((2-(3-butoxyphenyl)ethyl)amino)-N,N-dimethyl-; BDBM161090; NW-3509; SB18910; AS-48527; HY-17612; SY244487; CS-0014697; Q21098995; 2-[2-(3-butoxyphenyl)ethylamino]-N,N-dimethylacetamide; US9051240, 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dimethylacetamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Phase 2 | [1] | |
| Company |
Newron Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H26N2O2
|
|||
| Canonical SMILES |
CCCCOC1=CC=CC(=C1)CCNCC(=O)N(C)C
|
|||
| InChI |
1S/C16H26N2O2/c1-4-5-11-20-15-8-6-7-14(12-15)9-10-17-13-16(19)18(2)3/h6-8,12,17H,4-5,9-11,13H2,1-3H3
|
|||
| InChIKey |
GRHBODILPPXVKN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1092977-61-1
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated sodium channel (Nav) | Target Info | Blocker | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04461119) Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Newron Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.